To direct the Secretary of Health and Human Services to require public institutions of higher education that receive grants under the Medical Student Education program to include training for medical students relating to menopause in the curriculums of such institutions, and for other purposes.
Summary
HR9273 is a kitchen-table bill that directs medical schools receiving certain federal grants to include menopause training in their curricula. No direct market impact: zero appropriation, no mandate on private entities, and no immediate revenue effect for any publicly traded company.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR9273 is an early-stage education mandate with no funding or private-sector impact.
- 2.No publicly traded company faces a direct revenue or cost change from this bill.
- 3.Retail investors should ignore this bill for portfolio decisions; there are no material implications.
Market Implications
This bill does not affect any public company's revenue, costs, or competitive position. There are no market implications for any sector or ticker.
Full Analysis
- On June 11, 2026, Rep. Valerie Foushee (D-NC4) introduced HR9273, which would require public medical schools receiving grants under the Medical Student Education program to include menopause training. The bill was referred to the House Committee on Energy and Commerce — a standard first step. No further action has occurred. 2) The bill is an authorization-only measure with zero appropriated dollars. It does not create a spending program, tax credit, or procurement requirement. The mechanism is a curriculum mandate on grant-receiving institutions, not a market intervention. No money flows to private companies. 3) Structural winners and losers: This bill affects medical education accreditation, not drug pricing, device sales, or insurance reimbursement. Companies like $JNJ (menopause hormone therapy), $LLY (bone health), or $UNH (insurance coverage) see no revenue change because the bill does not alter prescription volume, coverage mandates, or provider reimbursement. 4) No real market data is available for this bill — it had zero price-relevant impact. 5) The bill must clear committee, pass the House, pass the Senate, and be signed by the President before any curriculum changes occur. Even if enacted, implementation is years away and applies only to federal grant recipients. Passage probability in the current Congress is low given the narrow scope and early stage.
Key Legislators
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Consolidated Appropriations Act, 2026
DELL FEDERAL SYSTEMS L.P: $1.0B Department of Veterans Affairs Contract
FERMI FORWARD DISCOVERY GROUP, LLC: $2.4B Department of Energy Contract
GENERAL MATTER, INC.: $900M Department of Energy Contract
Executive Order: Promoting Efficiency, Accountability, and Performance in Federal Contracting
Executive Order: Accelerating Medical Treatments for Serious Mental Illness
Commerce, Justice, Science; Energy and Water Development; and Interior and Environment Appropriations Act, 2026
ADVANCED TECHNOLOGY INTERNATIONAL: $304M Department of Health and Human Services Contract
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.